We welcome our new owners
New collaboration with Pharma
Oblique Therapeutics at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Oblique Therapeutics presents tumor growth inhibition and Treg-lowering data for OT-1096 in humanized mouse TNBC model at oncology congress ESMO
Oblique Therapeutics opens office in Stockholm, Sweden
We are hiring!
Research results on advanced cancer treatment published in renowned medical journal